MondegarAI
Pennant Investors, LP

Q2 2024 · 13F-HR

Pennant Investors, LPholdings as filed

Filed 2024-08-14 · accession 0000919574-24-004628

$382.6M
Reported value
46
Positions
2024-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
595112103MUMICRON TECHNOLOGY INC$56.7M14.8%431,000CommonSOLE
023135106AMZNAMAZON COM INC$46.4M12.1%240,000CommonSOLE
893641100TDGTRANSDIGM GROUP INC$41.4M10.8%32,371CommonSOLE
278768106SATSECHOSTAR CORP$38.3M10.0%2,153,209CommonSOLE
594918104MSFTMICROSOFT CORP$35.8M9.35%80,000CommonSOLE
02079K305GOOGLALPHABET INC$33.3M8.71%183,000CommonSOLE
03674X106ARANTERO RESOURCES CORP$27.3M7.13%836,000CommonSOLE
L7579L106PERIMETER SOLUTIONS SA$18.0M4.71%2,300,000CommonSOLE
03674X106ARANTERO RESOURCES CORP$16.3M4.26%500,000CALLSOLE
88337F105ODP1THE ODP CORP$15.7M4.11%400,000CommonSOLE
920253101VMIVALMONT INDS INC$11.0M2.87%40,000CommonSOLE
36828A101GEVGE VERNOVA INC$10.3M2.69%60,000CommonSOLE
92537N108VRTVERTIV HOLDINGS CO$10.0M2.60%115,000CommonSOLE
Q4982L109IRENIRIS ENERGY LTD$5.3M1.39%470,000CommonSOLE
21874A106CORZCORE SCIENTIFIC INC NEW$4.7M1.22%500,000CommonSOLE
03969K108ARQTARCUTIS BIOTHERAPEUTICS INC$1.6M0.42%170,900CommonSOLE
67080M103NRIXNURIX THERAPEUTICS INC$1.2M0.31%56,800CommonSOLE
670002401NVAXNOVAVAX INC$763,3980.20%60,300CommonSOLE
02155H200ALTALTIMMUNE INC$730,1700.19%109,800CommonSOLE
31572Q808FGENEURFIBROGEN INC$685,6430.18%768,400CommonSOLE
00847X104AGIOAGIOS PHARMACEUTICALS INC$651,1120.17%15,100CommonSOLE
31189P102FATEFATE THERAPEUTICS INC$479,2080.13%146,100CommonSOLE
89422G107TVTXTRAVERE THERAPEUTICS INC$458,6760.12%55,800CommonSOLE
29251M106ENTAENANTA PHARMACEUTICALS INC$455,2470.12%35,100CommonSOLE
4495851081K0IGM BIOSCIENCES INC$445,8630.12%64,900CommonSOLE
29479A108ERASERASCA INC$392,2320.10%166,200CommonSOLE
03969F109RCUSARCUS BIOSCIENCES INC$360,9510.09%23,700CommonSOLE
282559103ETNBGBP89BIO INC$356,4450.09%44,500CommonSOLE
98985Y108ZYMEZYMEWORKS INC$329,3370.09%38,700CommonSOLE
03969T109ARCTARCTURUS THERAPEUTICS HLDGS$318,9850.08%13,100CommonSOLE
019770106ALLOALLOGENE THERAPEUTICS INC$299,1720.08%128,400CommonSOLE
19249H103CHRSCOHERUS BIOSCIENCES INC$290,8130.08%168,100CommonSOLE
75943R102RLAYRELAY THERAPEUTICS INC$276,4480.07%42,400CommonSOLE
76029N106REPLREPLIMUNE GROUP INC$274,5000.07%30,500CommonSOLE
N90064101QUREUNIQURE NV$217,2800.06%48,500CommonSOLE
81750R102MCRB1EURSERES THERAPEUTICS INC$211,5670.06%292,300CommonSOLE
20454B104CMPXCOMPASS THERAPEUTICS INC$199,0000.05%199,000CommonSOLE
78667J108SG7SAGE THERAPEUTICS INC$190,0500.05%17,500CommonSOLE
37427G101GETRGETAROUND INC$188,7410.05%1,348,153CommonSOLE
556099109MGNXMACROGENICS INC$186,1500.05%43,800CommonSOLE
01671P100ALLKGUSDALLAKOS INC$186,1000.05%186,100CommonSOLE
019818103ALLOVIR INC$156,0160.04%215,700CommonSOLE
98943L107ZNTLZENTALIS PHARMACEUTICALS INC$132,5160.03%32,400CommonSOLE
09075P105BTAIEURBIOXCEL THERAPEUTICS INC$107,3920.03%83,900CommonSOLE
09609G100BLUEBIRD BIO INC$86,0190.02%87,400CommonSOLE
G4124C117GRABWGRAB HOLDINGS LIMITED$12,8880.00%80,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.